| A | B |
|---|
| Thank you for calling the ESA APPRISE Oncology program. | Call greeting |
| ESAs | Procrit, Aranesp, Epogen |
| Class of drugs | ESAs |
| Who has to enroll in the ESA APPRISE Oncology Program | Prescribers and Hospitals |
| This person can be a hostpital designee. | Director of Oncology |
| COBI | Centocor OrthoBiotech |
| Aranesp, Procrit and Epogen must be kept | refrigerated |
| Risks of using ESAs with myelosupressive chemotherapy | death, tumor growth |
| Prior to enrollment, prescribers are required to complete | online training |
| ESAs should not be prescriber to cancer patients undergoing myelosupressive chemotherapy if the expected outcome is | cure |
| Enrollment is preferred via | the ESA APPRISE Program website |
| What letters will be mailed to the target list? | Dear HCP and Dear Hospital letters |
| If a caller requests an enrollment form be mailed to them you should | take their name and number and advise that a supervisor will call them back. |
| Who should sign the Patient and HCP Acknowledgement Form? | The prescriber and the patient |
| What does a prescriber/hospital receive upon successful enrollment into the program? | An enrollment ID number |
| What 2 ways can a prescriber or hospital complete the required program training? | Via the website or in person with an Amgen or COBI field representative |
| What should the prescriber go over with the patient prior to having the patient sign the Patient and HCP Acknowledgement Form? | The Medication Guide |
| What vendor processes ESA APPRISE Oncology Program enrollment forms received by fax? | Secure 1 |
| Patient and HCP Acknowledgement Forms can be viewed within the REMS application as a | tif file |
| All triaged calls will be | warm transferred to the appropriate assistance line |
